TARGET: A Post-Approval Study to Evaluate Targeted SCS Spinal Cord Stimulation (SCS) Dorsal Root Ganglion (DRG) Stimulation for the Management of Moderate to Severe Chronic, Intractable, Pain of the Lower Limbs Due to CRPS Types I and II
ClinicalTrials.gov NCT02800863
Research payments
$276,456
Through program year 2020, $276,456 in research payments was reported against TARGET: A Post-Approval Study to Evaluate Targeted SCS Spinal Cord Stimulation (SCS) Dorsal Root Ganglion (DRG) Stimulation for the Management of Moderate to Severe Chronic, Intractable, Pain of the Lower Limbs Due to CRPS Types I and II, across 211 payments, paid by Abbott Laboratories.
- Paid by
- Abbott Laboratories
- ClinicalTrials.gov
- NCT02800863
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2020 | Research | $276,456 | 211 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Gregory Moore Eugene, OR Named on 10 payments
- Kenneth Chapman Staten Island, NY Named on 10 payments
- David Schultz Maple Grove, MN Named on 9 payments
- Andrew Will Edina, MN Named on 8 payments
- Corey Hunter New York, NY Named on 8 payments
- Rene Przkora Gainesville, FL Named on 8 payments
- Thomas Stauss Greenfield, WI Named on 8 payments
- Javid Baksh Asheville, NC Named on 7 payments
- Michael Fishell Henderson, NV Named on 7 payments
- Denis Patterson Sparks, NV Named on 7 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.